Table 3 Baseline characteristics of treatment groups
Demographic variable | Group | P value | |
|---|---|---|---|
Placebo | Active | ||
|  | (n 40) | (n 41) | – |
Age (years) | 65.2 (8.4) | 64.7 (6.3) | 0.784 |
Sex n male (female) | 17 (23) | 16 (25) | – |
Weight (kg) | 73.0 (63.4–84.0) | 72.8 (63.3–84.2) | 0.916 |
Height (m) | 1.69 (0.09) | 1.68 (0.08) | 0.587 |
BMI (kg/m2) | 25.5 (23.5–29.5) | 25.4 (23.4–29.5) | 0.860 |
Waist (cm) | 92.70 (82.63–102.50) | 89.75 (81.50–105.05) | 0.702 |
Hip (cm) | 104.28 (8.56) | 104.42 (8.74) | 0.944 |
Waist:hip | 0.89 (0.09) | 0.90 (0.10) | 0.605 |
Systolic BP (mmHg) | 130.9 (19.7) | 127.6 (20.3) | 0.469 |
Diastolic BP (mmHg) | 76.2 (8.6) | 74.6 (10.1) | 0.321 |
Plasma total 25(OH)D (nmol/L) | 62.5 (22.4) | 59.3 (25.2) | 0.539 |
Serum Homocysteine (µmol/L) | 11.05 (9.68–12.75) | 11.86 (10.29–15.05) | 0.047 |
Serum folate (nmol/L) | 18.0 (14.3–21.9) | 15.5 (11.8–21.6) | 0.123 |
Serum vitamin B12 (pmol/L) | 336 (235–449) | 310 (246–409) | 0.357 |
Plasma PLP (vitamin B6; nmol/L) | 61.7 (48.6–85.1) | 59.4 (44.5–74.1) | 0.487 |
Riboflavin (EGRac) | 1.29 (1.24–1.35) | 1.34 (1.25–1.43) | 0.168 |